Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
News and updates
The latest
Join us Sept. 23–24, 2026, in Rochester, Minnesota, for our annual outreach conference. This year’s event, Leveraging the Laboratory: Bold Thinking. Big Impact., focuses on how innovative approaches and strategic decision-making can drive meaningful results for health system laboratory outreach programs.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the role and expansion of at-home testing.
The nonprofit patient advocacy group called The MOG Project supports patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which is a rare and debilitating central nervous system demyelinating disorder. A team of Mayo Clinic neurologists, neuro-ophthalmologists, and the Autoimmune Neurology Laboratory at Mayo Clinic share a unique relationship with The MOG Project as they harness the power of patients’ experiences with MOGAD and their biospecimen data to advance the science behind this disease.
The United States will observe the Thanksgiving holiday on Thursday, Nov. 23. On this day, Mayo Clinic Laboratories will be open; however, specimen shipments and deliveries to our laboratories will not be made by the carriers. To safeguard specimens, please follow these shipping recommendations.
This week's research roundup feature: Renal fibrosis is now recognized as a main determinant of renal pathology to include chronic kidney disease. Deposition of pathological matrix in the walls of glomerular capillaries, the interstitial space, and around arterioles predicts and contributes to the functional demise of the nephron and its surrounding vasculature.
Patients want to use a laboratory that is easy to work with, and there are different definitions of “easy.” Ultimately, health systems want to have the patients they serve use their health system laboratories. If patients are choosing to go elsewhere, the laboratory should review and respond to several key patient experience factors.
In this month’s “Hot Topic,” Anne Tebo, Ph.D., discusses recent updates in the testing for anti-SS-A/Ro antibodies in systemic autoimmune rheumatic diseases.
In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., speaks with Robert Fazzio, M.D., Ph.D., assistant professor of radiology and chair of the Division of Breast Imaging at Mayo Clinic in Rochester, Minnesota.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how artificial intelligence (AI) has become a disruptive technology in the field of laboratory medicine, and how it can add value to patient care.
Eight years ago, Tamara Staley joined Mayo Clinic Laboratories’ Cardiovascular Sales team selling CV diagnostic testing to community hospitals. Now, she leads sales for Hematology and Oncology’s Central Region. Tamara is proud to help connect physicians and patients to a wide variety of oncology solid tumor testing that includes breast cancer testing.
This week's research roundup feature: Given the prevalence of dementia and the development of pathology-specific disease modifying therapies, high-value biomarker strategies to inform medical decision making are critical. In-vivo tau positron emission tomography (PET) is an ideal target as a biomarker for Alzheimer's disease diagnosis and treatment outcome measure.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss current focus areas found across the diagnostics industry and what transformative technologies are being explored around the world.
In a recent discovery by Mayo Clinic Laboratories, a novel hemoglobinopathy category was identified and termed epsilon gamma thalassemia. The first instance of the disorder was found in 2017 when an obstetric patient underwent a routine screening for blood-related illnesses such as sickle cell disease and thalassemia. Upon completion of additional tests, doctors found an abnormality they had never seen before.